scholarly journals Sjogren's Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports

Cureus ◽  
2020 ◽  
Author(s):  
Scott Zashin
Keyword(s):  
Sjögren’S Syndrome ◽  
Low Dose ◽  
Sjögren's Syndrome ◽  
Case Reports ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Additional Case ◽  
Clinical Benefits ◽  
Low Dose Naltrexone ◽  
Sjögren‘S Syndrome

Sjögren’s syndrome in the light of current research – literature review and selected case reports

2014 ◽  
Vol 67 (3) ◽  
pp. 409-422
Author(s):  
Maria Panaś ◽  
Maciej Rączkiewicz ◽  
Małgorzata Zaleska ◽  
Tomasz Kaczmarzyk ◽  
Konrad Kisielowski
Keyword(s):  
Literature Review ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Case Reports ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Research Literature ◽  
Sjögren‘S Syndrome

scholarly journals Anti-Ro/SAA Autoantibodies Might Represent the Antineuronal Antibodies Responsible for Cerebellar Degeneration in Sjögren's Syndrome 

2020 ◽  
Author(s):  
Syuichi Tetsuka ◽  
Tomohiro Suzuki ◽  
Tomoko Ogawa ◽  
Ritsuo Hashimoto ◽  
Hiroyuki Kato
Keyword(s):  
Sjögren’S Syndrome ◽  
Purkinje Cells ◽  
Sjögren's Syndrome ◽  
Case Reports ◽  
Cerebellar Atrophy ◽  
Central Nervous System Involvement ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Cerebellar Degeneration ◽  
Sjögren‘S Syndrome

Abstract Background: Neurologic disorders are one of the most common extraglandular manifestations of Sjögren's syndrome (SjS). Central neurologic symptoms can appear in about 5% of patients with SjS. However, only a few reports of cerebellar degeneration have been reported, and the clinical features and pathologic mechanisms of cerebellar degeneration associated with SjS are unclear.Patients and methods: We recently treated cerebellar degeneration in a patient with SjS. We analyzed the serum and cerebrospinal fluid (CSF) to detect anti-Ro/anti-SjS-related antigen A (SSA) and anti-La/anti-SjS-related antigen B (SSB) antibodies. We also searched the literature for previous case reports on SjS to evaluate the characteristics of cerebellar degeneration in patients with SjS and examined whether the Ro/SSA (Ro52/tripartite motif protein [TRIM]21) protein was expressed in murine cerebellum using immunohistochemistry.Results: Although all patients were positive for anti-Ro/SSA antibodies, some patients were negative for anti-La/SSB antibodies. Anti-Ro/SSA antibodies were observed in both serum and CSF. Anti-Ro/SSA antibodies were negative in the CSF of SjS patients without central nervous system involvement. Cerebellar atrophy was observed, and sequelae remained in the majority of the patients. Autopsy findings indicated a selective loss of Purkinje cells. Ro52/TRIM21 expression was detected throughout murine brains, including the hippocampus, cerebral cortex, and cerebellum. High Ro52/TRIM21 expression was observed in Purkinje cells.Conclusions: We described the characteristics of cerebellar degeneration in patients with SjS and Ro52/TRIM21 expression in Purkinje cells of murine cerebellar tissue sections. Thus, these outcomes indicated that anti-Ro/SSA autoantibodies were likely responsible for cerebellar degeneration in SjS.

Can low dose diagnostic dental radiation trigger Sjögren’s syndrome?

2007 ◽  
Vol 69 (5) ◽  
pp. 995-1000 ◽  
Author(s):  
Biji T. Kurien ◽  
Shirley A. Mathews ◽  
R. Hal Scofield
Keyword(s):  
Sjögren’S Syndrome ◽  
Low Dose ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Sjögren‘S Syndrome

scholarly journals Cytokines in Sjögren's syndrome: potential therapeutic targets

2010 ◽  
Vol 69 (6) ◽  
pp. 945-948 ◽  
Author(s):  
Nienke Roescher ◽  
Paul P Tak ◽  
Gabor G Illei
Keyword(s):  
Sjögren’S Syndrome ◽  
Inflammatory Cytokines ◽  
Low Dose ◽  
Sjögren's Syndrome ◽  
Biological Effects ◽  
Controlled Trial ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Early Results ◽  
Sjögren‘S Syndrome

The dysregulated cytokine network in Sjögren's Syndrome (SS) is reflected by local and systemic overexpression of pro-inflammatory cytokines and absent or low levels of anti-inflammatory cytokines. To date, the use of cytokine based therapies in SS has been disappointing. Oral administration of low dose interferon (IFN) α showed inconsistent efficacy in various studies and failed to achieve the primary endpoint in a pivotal randomised controlled trial. Similarly, neither of the two tumour necrosis factor (TNF)-α blockers tested (etanercept and infliximab) showed efficacy in placebo controlled trials. Although the rationale for low dose oral IFN treatment has not been firmly established, TNF blockade was based on solid preclinical data. Therefore, the reason for the lack of efficacy is unclear, but recent data suggest that unexpected biological effects of TNF antagonists may have contributed to this. Cytokines, given their central role in the pathogenesis of SS, remain attractive targets for future treatments, despite the disappointing early results. Inflammatory cytokines are obvious candidates, and agents against several of them are available or under development for other autoimmune diseases similar to SS. New candidate cytokines such as IL-17 and IL-12 and/or IL-23 may provide promising targets for SS. Additionally, as an alternative to systemic treatment, which has the risk of potentially severe side effects, the use of local cytokine directed therapy should be explored.

Agranulocytosis in Sjögren's syndrome: Two case reports and analysis of 11 additional reported cases

2002 ◽  
Vol 31 (5) ◽  
pp. 338-345 ◽  
Author(s):  
J. Friedman ◽  
A. Klepfish ◽  
E.B. Miller ◽  
V. Ognenovski ◽  
R.W. Ike ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Case Reports ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Sjögren‘S Syndrome
Sign in / Sign up

Export Citation Format

Share Document